📰 Programed Death Ligand News
Programed Death Ligand News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Programed Death Ligand. Real-time updates on events, politics, business and more.
May 20, 2024
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target ...
May 20, 2024
The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and 10
February 29, 2024
PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today the publication of clinical data on SON-1010 in Frontiers in Immunology. SON-1010, Sonnet's lead proprietary monofunct...
December 22, 2023
PRINCETON - Sonnet BioTherapeutics Holdings, Inc., a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today the publication of extensive preclinical data on...
April 18, 2023
PRINCETON, NJ / ACCESSWIRE / April 18, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced
April 18, 2023
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 ...